Chemotherapy for metastatic gastric cancer: past, present, and future.
about
Critical appraisal of trastuzumab in treatment of advanced stomach cancerGastric biomarkers: a global reviewOutcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.KLF16 promotes proliferation in gastric cancer cells via regulating p21 and CDK4.Up-regulation of neogenin-1 increases cell proliferation and motility in gastric cancer.FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.Determination of hypersensitivity to genotoxic agents among Escherichia coli single gene knockout mutantsCurcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathwaysOverexpression of CD151 predicts prognosis in patients with resected gastric cancer.Efficacy and safety of oxaliplatin, 5-Fluorouracil, and folinic Acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancerRefining docetaxel-containing therapy for gastric cancer.Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancerAntitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancerThymoquinone inhibits proliferation in gastric cancer via the STAT3 pathway in vivo and in vitro.Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.Pterostilbine, an active component of blueberries, sensitizes colon cancer cells to 5-fluorouracil cytotoxicity.Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer.Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer.Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapyREG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer.[The search for protein overexpression and HER2 gene amplification in gastric cancer by immunohistochemistry and in situ hybridization: experience of the CHU Hassan II of Fez]The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples.Prognostic assessment of different metastatic lymph node staging methods for gastric cancer after D2 resection.Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA studyForkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxelStilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death.EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma.Downregulation of caveolin-1 increases the sensitivity of drug-resistant colorectal cancer HCT116 cells to 5-fluorouracil.Trastuzumab for gastric cancer.Angiogenesis and lymphangiogenesis of gastric cancer.Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.Gastric metastasis in renal cell carcinoma: a case report and systematic review.Second-line chemotherapy for advanced gastric cancer in Korea.Metastatic gastric cancer treatment: a little slow but worthy progress.Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells.KLF15 Inhibits Cell Proliferation in Gastric Cancer Cells via Up-Regulating CDKN1A/p21 and CDKN1C/p57 Expression.Akt/AMPK/mTOR pathway was involved in the autophagy induced by vitamin E succinate in human gastric cancer SGC-7901 cells.
P2860
Q24604411-F99AA86E-6BD7-4D66-B0EB-341FC930F832Q26741859-F7E1A0A7-EAA6-4974-8AAD-47DFABBBED1AQ33389036-F86BF84E-99A8-451E-A92E-A7C5BFD67C82Q33389519-F2D10D8F-12A1-41BE-BC0A-A2911DEE94DFQ33850331-013D61F9-B838-49C8-AD99-061CC90ADA87Q33917654-796DC1A2-BC14-46CF-8636-C5E6455B1B3DQ33991617-8C047017-3DC8-4EFE-AD56-BB97CAFD7038Q34088322-71AF6575-287C-44A3-83FE-CF8079C13784Q34603280-DC40EA6D-2868-467A-9B7C-8F07791C162DQ34637700-55DE6E29-8F38-4993-9A64-F987CD7F1940Q35340883-6B14113D-F4D7-4229-91B0-E47F3E6544B7Q35445166-ABCE0941-87FB-4231-A3A6-B120C963CF5DQ35605606-6FDCE203-CDF4-4736-B175-54A2BFA40D24Q35720107-85B1722F-3D86-4CB5-96EE-E5E7AF5D77C7Q36001464-2C547989-B502-40A5-9F44-CBCB59ACE5F5Q36078921-F8844DCC-779C-42E8-9043-939610F2A19EQ36168444-79946FBF-676B-4C46-9958-734C17A5257FQ36280358-69196968-E1C1-4440-84CA-E49CB61A4346Q36368271-1CF00914-8539-47CE-ACCA-1A3E0987B09CQ36464803-7998D589-3113-43EA-9F25-33609AB69561Q36594051-F86CA2C4-C8CC-4AA3-A2FA-E2975BEEF332Q36595556-D4B7D37F-CFF6-43EA-807A-E574B1E9A472Q36613291-8820D2D7-BA63-48A7-A658-1862CAF60A3AQ36731208-924D42C0-6728-4ABD-AD15-2830E0C0A9F1Q36767776-6DF9B1BE-0B14-4A72-9EBC-12E435F38BFAQ37153952-23A0230A-47BE-412F-81C2-7252FD1AA7ECQ37373970-F8EBF0D5-F538-424D-8F6A-6AED37687309Q37552436-D9EB4EFA-DBC7-42DD-AAE6-635F3FCD33B7Q37590066-A0FF0259-B594-4F81-A0D3-DD7DA4C1B5EBQ37593963-81893190-38EC-4AFC-B024-63E35D7CAAF2Q37633540-EB9014BD-405F-4E9E-98A0-BC2C6F30E05FQ37724639-6E692343-B5D9-4D52-A97C-483BD2217046Q37724647-9812EAFA-3714-4BC5-876B-616118D45129Q37732285-9786AB0E-820A-4624-9649-0911F83D8E6BQ37761863-785654CD-4B29-4E83-BEB6-306AB1700317Q37992841-5977CC85-21AC-4BA8-801D-7FCD77037BBBQ38075499-6CC2B784-874E-4031-851C-5966E5B0A844Q38452910-6298C7AD-B12F-474B-A4C2-05193CE96B4BQ38706976-348383A0-F848-46AF-A1C9-D30BDB965D9AQ38735041-B58CAC1F-2BAD-4F03-9C9E-ED99CE6CF0FC
P2860
Chemotherapy for metastatic gastric cancer: past, present, and future.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy for metastatic gastric cancer: past, present, and future.
@en
Chemotherapy for metastatic gastric cancer: past, present, and future.
@nl
type
label
Chemotherapy for metastatic gastric cancer: past, present, and future.
@en
Chemotherapy for metastatic gastric cancer: past, present, and future.
@nl
prefLabel
Chemotherapy for metastatic gastric cancer: past, present, and future.
@en
Chemotherapy for metastatic gastric cancer: past, present, and future.
@nl
P1476
Chemotherapy for metastatic gastric cancer: past, present, and future.
@en
P2093
Atsushi Ohtsu
P304
P356
10.1007/S00535-008-2177-6
P577
2008-05-06T00:00:00Z